A Phase 3 Study of Induction Therapy Added to Chemoradiation and Pembrolizumab Maintenance Therapy for High-Risk Locally Advanced Cervical Cancer

Full Title

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer (NRG-GY037) (CIRB)

Purpose

The standard treatment for high-risk locally advanced cervical cancer is chemoradiation followed by maintenance therapy. Locally advanced means the cervical cancer has spread to nearby tissue or lymph nodes. In this study, researchers want to see if adding induction therapy before chemoradiation is more effective than standard therapy.

If you take part in this study, you will be randomly assigned to get one of these treatments:

• Chemoradiation (cisplatin, pembrolizumab immunotherapy, and radiation therapy) followed by maintenance therapy with pembrolizumab.
• Induction therapy with carboplatin, paclitaxel, and pembrolizumab, followed by standard chemoradiation and maintenance therapy.

Who Can Join

To join this study, there are a few conditions. You must:

• Have newly diagnosed high-risk locally advanced cervical cancer.
• Not have had prior treatment for cervical cancer.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information about this study or to see if you can join, please call Dr. Carol Aghajanian’s office at 646-888-4217.